Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$5.31
-0.2%
$6.55
$4.05
$10.80
$143.74M0.89145,306 shs151,450 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$1.74
-5.9%
$2.19
$1.60
$9.00
$15.96M0.8565,313 shs63,186 shs
The Westaim Co. stock logo
WEDXF
Westaim
$2.72
-0.4%
$2.67
$2.13
$2.99
$350.33M0.4629,107 shs11,250 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-3.27%-3.80%-21.07%-24.86%-45.38%
PAVmed Inc. stock logo
PAVM
PAVmed
-1.07%-6.09%-16.29%-25.10%-74.34%
The Westaim Co. stock logo
WEDXF
Westaim
-1.45%+1.12%-1.09%-0.05%+23.74%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.865 of 5 stars
3.53.00.00.02.50.00.6
PAVmed Inc. stock logo
PAVM
PAVmed
1.874 of 5 stars
3.00.00.04.33.20.80.0
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$12.00125.99% Upside
PAVmed Inc. stock logo
PAVM
PAVmed
2.00
Hold$21.001,106.90% Upside
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Latest PAVM, WEDXF, and CLPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/13/2024
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $9.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$23.95M6.00N/AN/A$0.86 per share6.17
PAVmed Inc. stock logo
PAVM
PAVmed
$2.45M6.51N/AN/A($3.35) per share-0.52
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M40.59$1.39 per share1.96$3.95 per share0.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$22.09M-$0.91N/AN/AN/A-92.21%-83.94%-47.92%5/7/2024 (Confirmed)
PAVmed Inc. stock logo
PAVM
PAVmed
-$64.18M-$9.33N/AN/A-2,617.25%N/A-85.99%5/21/2024 (Estimated)
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.09N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest PAVM, WEDXF, and CLPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.19N/A+$0.19N/AN/AN/A  
3/27/2024Q4 2023
The Westaim Co. stock logo
WEDXF
Westaim
N/A$0.26+$0.26$0.26N/A$1.67 million
3/26/2024Q4 2023
PAVmed Inc. stock logo
PAVM
PAVmed
N/A-$1.57-$1.57-$1.16N/A$1.05 million
3/12/2024Q4 2023
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.22-$0.19+$0.03-$0.19$6.40 million$6.81 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
$0.093.31%N/A6.92%N/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
0.47
4.87
3.80
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.45
0.45
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.11%
PAVmed Inc. stock logo
PAVM
PAVmed
12.60%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
10727.07 million25.42 millionOptionable
PAVmed Inc. stock logo
PAVM
PAVmed
1079.17 million8.02 millionOptionable
The Westaim Co. stock logo
WEDXF
Westaim
7128.80 million123.54 millionNot Optionable

PAVM, WEDXF, and CLPT Headlines

SourceHeadline
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM
Westaim earnings preview: what Wall Street is expectingWestaim earnings preview: what Wall Street is expecting
markets.businessinsider.com - April 14 at 10:42 AM
Heres what Wall Street expects from Westaims earnings reportHere's what Wall Street expects from Westaim's earnings report
markets.businessinsider.com - April 6 at 12:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ClearPoint Neuro logo

ClearPoint Neuro

NASDAQ:CLPT
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
PAVmed logo

PAVmed

NASDAQ:PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.